Document:

Exhibit 10.4

 

Indemnification Agreement

 

 

This Indemnification Agreement (this "Agreement")
is made as of ___________, 2013, by and between Alcobra Ltd., a company organized
and existing under the laws of Israel (the "Company") and ____________
I.D. No / Passport No ____________ ("Indemnitee").

 

 

WHEREAS, the Company desires to attract
and retain qualified directors and officers and to provide them with protection against liability and expenses incurred while acting
in that capacity; and

 

WHEREAS, Indemnitee is director or officer
of the Company; and

 

WHEREAS, in order to induce Indemnitee
to serve as a director or officer of the Company, the Company agrees to indemnify Indemnitee upon certain occurrences, all under
the terms of this Agreement.

 

Now, therefore, the parties agree as follows:

 

		1.	Indemnity. The Company hereby agrees, subject to the limitations set forth in this Agreement
and to applicable law:

 

To indemnify Indemnitee to the
greatest extent possible under applicable law against any liability or expense in respect of any acts or omissions of Indemnitee
in his capacity as a director or officer of the Company, as follows:

 

(i) a financial obligation imposed
on Indemnitee in favor of another person by a court judgment, including a compromise judgment or an arbitrator's award approved
by court;

 

(ii) reasonable litigation expenses,
including attorneys' fees, expended by Indemnitee or charged to him by a court, in a proceeding instituted against him by the Company
or on its behalf or by another person, or in a criminal charge from which he was acquitted or in any criminal proceeding of a crime
which does not require proof of mens rea (criminal intent) in which the Indemnitee is convicted, or due to an investigation or
a proceeding conducted against him by an authority authorized to conduct an investigation or a proceeding, pursuant to which no
indictment was filed against him and no monetary liability was imposed on him as an alternative to a criminal proceeding, or due
to an investigation or a proceeding conducted against him by an authority authorized to conduct an investigation or a proceeding,
pursuant to which no indictment was filed against him but a monetary liability was imposed on him as an alternative to a criminal
proceeding, for a crime which does not require a finding of mens rea (criminal intent) (collectively referred to hereinafter as
a "Claim");

 

(iii) a payment which Indemnitee
is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law, 1968, as amended
(the "Securities Law"), if applicable, and expenses that Indemnitee incurs in connection with a proceeding under
Chapters H'3, H'4 or I'1 of the Securities Law, if applicable, including reasonable legal expenses, which term includes attorney
fees; and

 

(iv) any other obligation or
expense in respect of which it is permitted or will be permitted under the Companies Law, 5759-1999, to indemnify an officer or
director, subject to and in accordance with all applicable law.

 

The above indemnification will
also apply to any action taken by the Indemnitee in his capacity as a director and/or officer of any other company controlled,
directly or indirectly, by the Company (a “Subsidiary”) or in his capacity as a director, officer or observer
at board of directors’ meetings, of a company not controlled by the Company but where his appointment as a director, officer
or observer results from the Company’s holdings in such company (“Affiliate”).

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 2 -

    
 

		2.	General Limitations on Indemnity. If, when and to the extent that a final judicial determination
is made, as to which all rights of appeal therefrom have been exhausted or lapsed, the Indemnitee would not be permitted to be
so indemnified as provided under this Agreement, the Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees
to reimburse the Company) for all such amounts theretofore paid. Indemnitee’s obligation to reimburse the Company for any
advance expenses or other sums paid hereunder shall be unsecured and no interest shall be charged thereon.
	 	 	 

		3.	Limitations on Indemnity.
	 	 	 

		3.1.	The Company undertakes to indemnify Indemnitee, with respect to Section 1(i) above, and in accordance
with the terms of this Agreement up to a total amount of US$__________ (__________
United States Dollars) in the aggregate, under the circumstances of indemnification of Indemnitee as set forth in this Agreement.
	 	 	 

		3.2.	Indemnitee shall not be entitled to indemnification under Section 1, for financial obligations
imposed arising from any of the following: (i) a breach of the duty of fiduciary by Indemnitee, except, to the extent permitted
by law, for a breach of the duty of fiduciary by the Indemnitee to the Company, a Subsidiary or an Affiliate while acting in good
faith and having reasonable cause to assume that such act would not prejudice the interests of the Company, Subsidiary or Affiliate,
as applicable; or (ii) a violation of the Indemnitee’s duty of care towards the Company, which was committed intentionally
or recklessly, except if it was done in negligence only; or (iii) an act committed with the intention to realize a personal unlawful
profit; or (iv) a fine or monetary penalty imposed on Indemnitee (excluding a fine or monetary penalty imposed pursuant to the
conviction of a crime which requires proof of mens rea (criminal intent)); or (v) a counterclaim made by the Company or in its
name in connection with a claim against the Company filed by Indemnitee, other than (a) by way of defense or by way of third party
notice in connection with claim brought against the Indemnitee, or (b) in specific cases in which the Company’s Board of
Directors has approved the initiation or bringing of such suit by Indemnitee, which approval shall not be unreasonably withheld.
	 	 	 

		3.3.	The indemnification amount actually paid shall be limited to those amounts not covered by the Company’s
directors and officers insurance policy (the “D&O Policy”), such that Indemnitee will not be entitled to
payment from the Company for amounts which Indemnitee has actually obtained under the D&O Policy.
	 	 	 

		3.4.	Subject to the provisions of this Section 3, the indemnification hereunder will, in each case,
cover all sums of money that the Indemnitee will be obligated to pay, in those circumstances for which indemnification is permitted
under the law.
	 	 	 

		3.5.	The Company will be entitled to reimbursement of amounts collected from a third party in connection
with liabilities indemnified hereunder. Such reimbursement shall not exceed the amount the Company has paid to the Indemnitee.
	 	 	 

		4.	Limitation of Categories of Claims. The indemnification pursuant to Section 1(i) above,
shall only relate to liabilities arising in connection with acts or omissions of Indemnitee in respect of the following events
and circumstances which are deemed by the Company's Board of Directors to be foreseeable at the date hereof:

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 3 -

    
 

		4.1.	The offering of securities by the Company and/or by a shareholder thereof to the public and/or
to private investors or the offer by the Company to purchase securities from the public and/or from private investors or other
holders pursuant to a prospectus, agreements, notices, reports, tenders and/or other proceedings;
	 	 	 

		4.2.	Occurrences in connection with investments in or by the Company and/or Subsidiary and/or Affiliate
in other corporations whether before and/or after the investment is made, entering into the transaction, the execution, development
and monitoring thereof, including actions taken by the Indemnitee in the name of the Company and/or Subsidiary and/or Affiliate
as a director, officer, employee and/or board observer of the corporation which is the subject of the transaction and the like;
	 	 	 

		4.3.	The sale, purchase and holding of negotiable securities or other investments for or in the name
of the Company and/or Subsidiary and/or Affiliate;
	 	 	 

		4.4.	Actions in connection with the merger of the Company and/or any Subsidiary and/or any Affiliate
with or into another entity;
	 	 	 

		4.5.	Actions in connection with the sale of the operations, assets and/or business, or part thereof,
of the Company and/or Subsidiary and/or Affiliate;
	 	 	 

		4.6.	Without derogating from the generality of the above, actions in connection with the purchase or
sale of companies, legal entities or assets, licensing or acquisition of rights in products, assets or technologies of other persons
or legal entities, and the sale, licensing or grant of license in the same to other persons or legal entities, and the division
or consolidation thereof;
	 	 	 

		4.7.	Actions taken in connection with labor relations and/or employment matters (including employment-related
benefits) in the Company and/or Subsidiary and/or Affiliate and trade relations of the Company and/or Subsidiary and/or Affiliate,
including with employees, independent contractors, customers, suppliers and various service providers;
	 	 	 

		4.8.	Actions in connection with the developing, testing and manufacturing of products (including a third
party’s products, solutions and technologies) by the Company and/or Subsidiary and/or Affiliate or in connection with the
distribution, sale, license or use of such products, solutions or technologies, and management of projects whether of the Company
and/or Subsidiary and/or affiliate and/or any third party;
	 	 	 

		4.9.	Actions relating to the promotion, offering and/or support of the products, solutions and technologies
in the fields of operation of the Company, any of its Subsidiaries or Affiliates as shall exist from time to time.
	 	 	 

		4.10.	Actions taken in connection with the intellectual property of the Company and/or Subsidiary and/or
Affiliate and its protection, including the registration or assertion of rights to intellectual property and the defense of claims
related to intellectual property or any claim or demand made for actual or alleged infringement, misappropriation, or misuse of
any third party's intellectual property rights by the Company, its Subsidiaries or Affiliates, including without limitation confidential
information, patents, copyrights, design rights, service marks, trade secrets, copyrights, and misappropriation of ideas by the
Company, its Subsidiaries or Affiliates;
	 	 	 

		4.11.	Actions taken pursuant to or in accordance with the policies and procedures of the Company and/or
Subsidiary and/or Affiliate, that have been decided upon, whether such policies and procedures are published or not, and actions
relating to the operations and management of the Company and/or of any Subsidiaries and/or Affiliates.
	 	 	 

		4.12.	Occurrences resulting from the Company’s and/or Subsidiary’s and/or Affiliate’s
status as a public company, and/or from the fact that the Company’s securities were offered to the public and/or are traded
on a stock exchange, whether in the U.S. or elsewhere;

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 4 -

    
 

		4.13.	Any claim or demand made by any lenders or other creditors or for monies borrowed by, or other
indebtedness of, the Company and\or Subsidiary and/or any Affiliate.
	 	 	 

		4.14.	Any claim or demand made by any third party suffering any personal injury or damage to business
or personal property through any act or omission attributed to the Company or its Subsidiaries or its Affiliates, or their respective
employees, agents or other persons acting or allegedly acting on their behalf.
	 	 	 

		4.15.	Any claim or demand made by suppliers, contractors or other third parties transacting any form
of business with the Company in the ordinary course of their respective businesses, relating to the negotiations or performance
of such transactions, representations or inducements provided in connection thereto or otherwise.
	 	 	 

		4.16.	Any claim or demand made in connection with any transaction not in the ordinary course of business
of either the Company or the party making such claim (including any transaction with directors or officers of the Company or any
controlling shareholder of the Company).
	 	 	 

		4.17.	Any claim or demand made directly or indirectly in connection with complete or partial failure,
by the Company and\or Subsidiary and/or Affiliate, or their respective directors, officers and employees, to pay, report, keep
applicable records or otherwise, any federal, state, municipal or foreign taxes or other mandatory payments of any nature whatsoever,
including, without limitation, income, sales, use, transfer, excise, value added, registration, severance, stamp, occupation, customs,
duties, real property, personal property, capital stock, social security, unemployment, disability, payroll or employee withholding
or other withholding, including any interest, penalty or addition thereto, whether disputed or not.
	 	 	 

		4.18.	Any actions or decisions relating to insurance matters and/or risk management of the Company.
	 	 	 

		4.19.	The filing of a report and/or announcement required by the Companies Law and/or any securities
law which is applicable or may be applicable to the Company from time to time, including the U.S. Securities Laws, including the
regulations pertaining to these laws, the Israeli Securities Law - 1968, and/or according to rules and/or regulations adopted by
the NASDAQ or any other stock exchange and/or securities market and/or any law of any other country pertaining to these issues
and/or the failure to file such a report and/or announcement, and/or actions relating to tender offers of the Company, including
actions relating to delivery of opinions in relation thereto.
	 	 	 

		4.20.	Any decision regarding a distribution, as defined in the Companies Law, including a distribution
pursuant to a court order, and/or repurchase of shares or returns of capital or loans of the Company.
	 	 	 

		4.21.	Any actions in connection with the change in the Company's structure and/or a reorganization of
the Company, including any arrangement between the Company and its shareholders and/or creditors according to the Companies Law,
and/or any decision relating to these issues including, but not limited to, a change in the Company's capital, the establishment
of subsidiaries and/or their liquidation or sale, and/or all allotments or distributions.
	 	 	 

		4.22.	Approval of corporate actions, including the approval of acts of the Company's management, its
guidance and its supervision.
	 	 	 

		4.23.	Any claim or demand made in connection with any expression of opinion or saying made in good faith
during the course of performance of duties and in connection with the performance of duties, including during meetings of the board
of directors or committees of the Company;

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 5 -

    
 

		4.24.	Any administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters,
directives, claims, liens, investigations, proceedings or notices of noncompliance or violation by any governmental entity (in
Israel or abroad), including the Office of the Chief Scientist or the Investment Center of the Israeli Ministry of Industry and
Commerce, the Israeli Antitrust Authority or the Israel Securities Authority, or other person alleging the failure to comply with
any statute, law, ordinance, rule, regulation, order or decree of any governmental entity applicable to the Company and/or Subsidiary,
or any of their respective businesses or operations.
	 	 	 

		4.25.	Any claim or demand made by purchasers, holders, lessors or other users of products of the Company,
for damages, losses or personal injuries related to such products.
	 	 	 

		4.26.	Any claim or demand made in connection with any preparation or formulation of work plans, including
pricing, marketing, distribution, instructions to employees, customers and suppliers, and collaboration with competitors.
	 	 	 

		4.27.	Any acts in regard of invasion of privacy, participation and/or non-participation at Board meetings
and/or voting and/or abstention from voting at Board meetings, approval of corporate actions, claims of failure to exercise business
judgment.
	 	 	 

		4.28.	Claims of failure to exercise business judgment and a reasonable level of proficiency, expertise
and care in regard of the Company's business.
	 	 	 

		4.29.	Violations of laws requiring the Company to obtain regulatory and governmental licenses, permits
and authorizations in any jurisdiction.
	 	 	 

		4.30.	Decisions and/or actions relating to environmental compliance, including pollution, contamination
and hazardous materials.
	 	 	 

		4.31.	Granting of liens on Company assets and granting guarantees on behalf of the Company.
	 	 	 

		4.32.	Claims in connection with publishing or providing any information, including any filings with governmental
authorities in the U.S., Israel and elsewhere, on behalf of the Company, in the circumstances required under applicable laws.
	 	 	 

		4.33.	Claims in connection with the preparation, approval or providing of any annual or quarterly financial
statements, profit and loss statements, balance sheets and similar financial information or forecasts.
	 	 	 

		4.34.	Any of the forgoing actions or decisions relating or otherwise applicable to any Subsidiary or
Affiliate of the Company.
	 	 	 

		4.35.	Any claim or demand, not covered by any of the categories of events described above, which, pursuant
to any applicable law, a director or officer of the Company may be held liable to any government or agency thereof, or any person
or entity, in connection with actions taken by such director or officer in such capacity.
	 	 	 

		5.	Expenses; Indemnification Procedure. The Company shall advance Indemnitee all expenses incurred
by Indemnitee in connection with a Claim on the date on which such amounts are first payable (“Time of Indebtedness”),
and with respect to items mentioned in Section 1(ii) above, even prior to a court decision, but has no duty to advance payments
in less than twenty (20) days (but in any event not later than thirty (30) days) following delivery of a written request therefor
by Indemnitee to the Company. Advances given to cover legal expenses in criminal proceedings will be repaid by Indemnitee to the
Company, if such proceedings are concluded in such manner that would not have entitled the Indemnitee to indemnification under
Section ‎1 above. Additionally, the Company shall make available to Indemnitee any securities and/or guarantees which
Indemnitee will be required to provide in the framework of any action or proceeding and/or according to any interim decision, including
arbitration proceedings, and including with respect to the exchange of any attachments imposed on Indemnitee's assets.

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 6 -

    
 

		6.	Notification and Defense of Claim. If any Claim is brought against Indemnitee in respect
of which indemnity may be sought under this Agreement:
	 	 	 

		6.1.	The Indemnitee shall promptly notify the Company of any legal proceedings initiated and of all
possible or threatened legal proceedings without delay following first becoming aware thereof, and the Indemnitee shall deliver
to the Company, or to such person as it shall advise, without delay all documents received in connection with these proceedings.
Similarly, the Indemnitee must advise the Company on an ongoing and current basis concerning all events which the Indemnitee suspects
may give rise to the initiation of legal proceedings against the Indemnitee. Notice to the Company shall be directed to the Chief
Executive Officer with a copy to the General Counsel and the Chief Financial Officer of the Company as per Section 19 hereof, or
if the Indemnitee is then the Chief Executive Officer of the Company, such notice shall be directed to the Chairman of the Board
and the other addressees.
	 	 	 

		6.2.	The Company will be entitled to participate therein at its own expense or to assume the defense
thereof and to employ counsel reasonably satisfactory to Indemnitee. Indemnitee shall have the right to employ its own counsel
in connection with any such Claim and to participate in the defense thereof, but the fees and expenses of such counsel shall be
at the expense of Indemnitee unless: (i) the Company shall not have assumed the defense of the Claim, or (ii) the named
parties to any such action (including any impleaded parties) include both Indemnitee and the Company, and Indemnitee shall have
reasonably concluded that joint representation is inappropriate under applicable standards of professional conduct due to a conflict
of interest between Indemnitee and the Company, in either of which events reasonable fees and expenses of such counsel to Indemnitee
shall be borne by the Company. However, in no event will the Company be obligated to pay the fees or expenses of more than one
firm of attorneys representing Indemnitee in connection with any one Claim or separate but substantially similar or related Claims
in the same jurisdiction arising out of the same general allegations or circumstances. For the avoidance of doubt, in the case
of criminal proceedings the Company and/or the attorneys as aforesaid will not have the right to plead guilty in Indemnitee’s
name or to agree to a plea-bargain in his name without his prior written consent. Furthermore, in a civil proceeding (whether before
a court or as a part of a compromise arrangement), the Company and/or its attorneys will not have the right to admit to any occurrences
that are not indemnifiable pursuant to this Agreement and/or pursuant to law, without Indemnitee’s prior written consent.
However, the aforesaid will not prevent the Company and/or its attorneys as aforesaid, with the approval of the Company, to come
to a financial arrangement with a plaintiff in a civil proceeding without Indemnitee’s consent so long as such arrangement
will not be an admittance of an occurrence not fully indemnifiable pursuant to this Agreement and/or pursuant to law and further
provided that any such settlement or arrangement does not impose on Indemnitee any liability or limitation.
	 	 	 

		6.3.	The Company shall not be liable to indemnify Indemnitee for any amounts paid in settlement of any
Claim effected without the Company's written consent. Indemnitee shall give the Company such information and cooperation as may
be required.
	 	 	 

		6.4.	The Indemnitee will fully cooperate with the Company and/or any attorney as aforesaid in every
reasonable way as may be required within the context of their conduct of such legal proceedings, including but not limited to the
execution of power(s) of attorney and other documents, provided that the Company shall cover all costs incidental thereto such
that the Indemnitee will not be required to pay the same or to finance the same himself.
	 	 	 

		7.	Subrogation. In the event of payment under this Agreement from Company to Indemnitee, the
Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all
documents reasonably required and shall do everything that may be reasonably necessary to secure such rights, including the execution
of such documents necessary to enable the Company effectively to bring suit to enforce such rights.

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 7 -

    
 

		8.	Primacy of Indemnification. The Company hereby acknowledges that Indemnitee has or may have
certain rights to indemnification, advancement of expenses and/or insurance provided by the Indemnitee or by the party or parties
who appointed the Indemnitee and certain of such party's affiliates (collectively, the “Appointing Party”).
The Company hereby agrees, with respect to Indemnitee's right to indemnification pursuant hereto: (i) that the Company is the indemnitor
of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Appointing Party or its (or the Indemnitee's)
insurer to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary),
(ii) that, subject to the provisions hereof, the Company shall be required to advance the full amount of expenses incurred by Indemnitee
and indemnifiable hereunder and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid
in settlement to the extent legally permitted and as required by the Company’s Articles Association (or any agreement between
the Company and Indemnitee) all subject to the provisions hereof, without regard to any rights Indemnitee may have against the
Appointing Party or its (or the Indemnitee's) insurer, and, (iii) that the Company irrevocably waives, relinquishes and releases
the Appointing Party or its (or the Indemnitee's) insurer from any and all claims against the Appointing Party or its (or the Indemnitee's)
insurer for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no
advancement or payment by the Appointing Party or its (or the Indemnitee's) insurer on behalf of an Indemnitee with respect to
any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Appointing Party
or its (or the Indemnitee's) insurer shall have a right of contribution and/or be subrogated to the extent of such advancement
or payment to all of the rights of recovery of Indemnitee against the Company. The Company and the Indemnitee agree that the Appointing
Party or its (or the Indemnitee's) insurer are express third party beneficiaries of the terms hereof.
	 	 	 

		9.	Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement
to indemnification by the Company for some or a portion of the expenses actually or reasonably incurred by Indemnitee in connection
with a Claim or Claims, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for
the portion of such expenses to which Indemnitee is entitled.
	 	 	 

		10.	Other Indemnification. Except to the extent provided in Section 8 above, the Company will
not indemnify Indemnitee for any liability with respect to which Indemnitee has received payment by virtue of an insurance policy
or other indemnification agreement, other than for amounts, which are in excess of the amount paid to Indemnitee pursuant to such
policy or agreement and other than a deductible payable by the Indemnitee under an insurance policy or indemnification agreement.
	 	 	 

		11.	Collection from a Third Party. The Company will be entitled to any amount collected from
a third party in connection with a Claim or Claims actually indemnified hereunder by the Company.
	 	 	 

		12.	Non-Exclusivity. The rights of the Indemnitee hereunder shall not be deemed exclusive of
any other rights he may have under the Company’s Articles of Association or applicable law or otherwise, and to the extent
that during the indemnification period hereunder the rights of the then existing directors and officers are more favorable to such
directors or officers than the rights currently provided thereunder or under this Agreement to Indemnitee, Indemnitee shall be
entitled to the full benefits of such more favorable rights.
	 	 	 

		13.	Exemption. The Company hereby exempts Indemnitee, to the fullest extent permitted by
                                                            law, from any liability, or any part of liability, for damages caused as a result of a breach of his duty of care to the
                                                            Company, provided that in no event shall he be exempt with respect to any actions listed in Section ‎3.2 above.

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 8 -

    

 

		14.	Post Factum Indemnification. It is hereby clarified that nothing in here shall limit the
Company’s right to indemnify the Indemnitee post factum, for any and all amounts or events, without limitation.
	 	 	 

		15.	Severability. Each of the provisions of this Agreement is a separate and distinct agreement
and independent of the others, so that if any provision hereof shall be held to be invalid or unenforceable for any reason, such
invalidity or unenforceability shall not affect the validity or enforceability of the other provisions hereof. If such invalid
or unenforceable undertaking may be modified or amended so as to be valid and enforceable as a matter of law, such undertaking
will be deemed to have been modified or amended, and any competent court or arbitrator are hereby authorized to modify or amend
such undertaking, so as to be valid and enforceable to the maximum extent permitted by law.
	 	 	 

		16.	Termination of Services.For the avoidance
of doubt, the Company will indemnify Indemnitee even if at the relevant Time of Indebtedness Indemnitee is no longer a director
or officer of the Company or of a Subsidiary or a director, officer and/or board observer of an Affiliate, as applicable, provided,
that the obligations are in respect of actions taken by the Indemnitee while serving as a director, officer and/or board observer,
as aforesaid, and in such capacity.
	 	 	 

		17.	Attorneys' Fees. In the event of any litigation or other action or proceeding to enforce
or interpret this Agreement, the prevailing party as determined by the court shall be entitled to an award of its reasonable attorneys'
fees and other costs, in addition to such relief as may be awarded by a court or other tribunal.
	 	 	 

		18.	Further Assurances. The parties will do, execute and deliver, or will cause to be done,
executed and delivered, all such further acts, documents and things as may be reasonably required for the purpose of giving effect
to this Agreement and the transactions contemplated hereby. Notwithstanding anything to the contrary, if for the validation of
any of the undertakings in this Agreement any act, resolution, approval or other procedure is required, the Company undertakes
to cause them to be done or adopted in a manner which will enable the Company to fulfill all its undertakings as aforesaid.
	 	 	 

		19.	Notice. All notices, requests, demands and other communications under this Agreement shall
be in writing and shall be deemed duly given (i) if delivered by hand or by fax or other means of electronic communication
and receipted for by the party addressee, on the date of such receipt, or (ii) if mailed by certified or registered mail with
postage prepaid, on the third business day after the date postmarked.
	 	 	 

		20.	Entire Agreement; Amendments. This Agreement constitutes the entire agreement between the
parties with respect to its subject matter, and supersedes and cancels all prior agreements, proposals, representations and communications
between the parties regarding the subject matter hereof. No amendment, modification, termination or cancellation of this Agreement
shall be effective unless it is in writing and signed by the parties hereto.
	 	 	 

		21.	Binding Effect; No Assignment. This Agreement shall be binding upon Indemnitee and the Company,
their successors and assignees, and shall inure to the benefit of Indemnitee, his heirs, personal representatives and assignees
and to the benefit of the Company, its successors and assignees. Indemnitee shall not assign or otherwise transfer his rights under
this Agreement and any attempt to assign or transfer such rights shall be deemed null and void.
	 	 	 

		22.	Governing Law; Jurisdiction. This Agreement shall be interpreted and enforced in accordance
with the laws of the State of Israel, without regard to their rules of conflict of laws, and any dispute arising from or in connection
with this Agreement is hereby submitted to the sole and exclusive jurisdiction of the competent courts in Tel Aviv, Israel.

 

    	{Exhibit 10.4 -- Form of Indemnification Agreement; 1}

    	- 9 -

    
 

		23.	Construction. The undertakings of the parties pursuant to this Agreement shall be widely
construed and in a manner designated to give them effect, to the fullest extent permissible under law. In the event of any contradiction
between the provisions of this Agreement and any provision of law that is not dispositive or which cannot be amended, the provision
of law shall prevail but the same shall not impair or derogate from the validity of the other provisions hereunder.
	 	 	 

		24.	Counterpart Signatures. This Agreement may be executed in counterparts, both of which when
taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that two parties need not sign the same counterpart. In the event
that any signature is delivered by facsimile or PDF transmission, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile
or PDF signature page were an original thereof.

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the day and year first above written.

 

 

	
        Alcobra Ltd.

        Name:______________

        Title:______________
	 	_____________

 

 

{Exhibit 10.4 -- Form of Indemnification
Agreement; 1}Exhibit 10.8

  

[Free Translation
from Hebrew]

 

State of Israel

Ministry of
Trade and Industry

Industrial Research
and Development Administration

Office of Chief
Scientist

 

 

Jerusalem,
07-12-2009 

 

Letter
of Approval Number: 42073

(Fiscal
regulation: 38020101)

Group:
13

  

To

Alcobra Ltd. 

POB – 

Givatayim 53454

Letter of
Approval

 

	 	1.	We hereby inform you that the research committee, by virtue of its authority according to Article 17 of the Law for the Encouragement of Research and Development in the Industry, 5744-1984 (hereinafter: the “R&D Law”), has resolved in its meeting on 03/08/2009 to approve the program as submitted by you on 24/05/2009, which subject matter is:

 

	 	a.	Subject of approved program: Development of Treatment for Attention Deficit Disorder and Memory Impairment 

 

	 	b.	Performing the approved program: Alcobra Ltd.

 

	 	 	Registration Number: 514098995

(hereinafter
– the “Approved Program”)

 

	 	2.	
        a. The research and
        development expenses approved for the performance of the approved program will be in an amount of up to: NIS 2,094,300.
        

        In words: Two
        Million, Ninety Four Thousand and Three Hundred NIS.

        b. The rate of grant
        approved is 30% of the development expenses (addition with respect to a national priority zone A/ line of confrontation),
        which is up to an amount of NIS 628,290.

        In words: Six
        Hundred and Twenty Eight Thousand, Two Hundred and Ninety NIS.

        

 

	 	3.	The approval is conditioned upon fulfillment of the provisions of the law, regulations, rules and procedures promulgated thereunder and subjesct to the following terms:

 

	 	a.	The approved program will be performed as detailed in your request within a period of 12 months – from 01/05/2009 and until 30/04/2010 (hereinafter: the “Performance Period”).

 

	 	b.	
        (1) You must inform the Office of the Chief
        Scientist about every change in the control of the recipient of the grant in the company’s shares and/or in one of the following
        controlling means: (a) the right to vote in the company’s general meetings; (b) the right to appoint directors
        in the company; (c) the right to participate in the company’s profits.

        (2) Transferring
        any percentage of the controlling means stated in subsection (1) to a non-Israeli resident or to a foreign company, which
        make the non-Israeli resident or foreign company an interested party as defined in the Securities Law, 1968, requires notification
        to Office of the Chief Scientist and a written undertaking of the non-Israeli resident or the foreign company to the R&D Law.

        The letter of approval
        shall be signed in the form existing in the office of the Chief Scientist and in the website of the Ministry of Industry, Trade
        and Employment.

 

	 	c.	
        Additional terms:

        Payment
        per performance.

        Royalties shall be paid on income from
        Metadoxin Extended (Controlled) Release Tablets.

 

	 	d.	See the appendix in the matter of intellectual property.

 

	 	e.	In the event of pledging the company’s assets to an Israeli bank against credit, the company must ensure that the pledge shall be subject to the R&D Law.

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    
 

	 	f.	If the plan is connected to an agreement with an academic institution or an academic implementation company, the company must ensure that the agreement is subject to the provisions of the R&D Law.

 

 

	 	 	Sincerely,
	 	 	 
	 	 	/s/ 
	 	 	Dr. Eli Ofer

The Chief Scientist

 

Attached:

 

	 	1.	Budget breakdown appended to the letter of approval.
	 	2.	Letter of commitment.
	 	3.	Rules determined by the research committee for the performance of the provisions of the Law.
	 	4.	Letter of approval intellectual property appendix.

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    

 

[Free Translation
from Hebrew]

 

State of Israel

Ministry of
Trade and Industry

Industrial Research
and Development Administration

Office of Chief
Scientist / Office Controller

 

07-12-2009

 

To:

Alcobra Ltd. 

POB – 

Givatayim 53454

Budget Appendix
with respect to Research and Development File Number 42073

Appendix to
Letter of Approval

 

Subject to the letter
of approval signed by the Chief Scientist from 07/12/2009 and following the decision of the research committee pursuant
to Article 17(c) from 03/08/2009 with respect to research and development file which number is 42073

 

Subject
of approved program: Development of Treatment for Attention Deficit Disorder and Memory Impairment 

 

and performed by Alcobra
Ltd.

 

Period of research:
from 01/05/2009 until 30/04/2010

 

The office’s
budget commitment in an amount of up to NIS 628,290 is hereby approved for the performance of research and development
expenses for the approved program.

 

	 	 	 	 	 
	
        /s/ 
	 	 	 	
        /s/ 

	Vice Chief Scientist	 	 	 	
        Office controller, the Ministry of

        Industry, Trade and Employment

         

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    

 

[Summary Translation
from Hebrew]

 

This page forms an
integral part of the letter of approval

 

Details
of the budget for research and development in the matter of: Development of Treatment for Attention Deficit Disorder
and Memory Impairment 

 

Performance period
from 01/05/2009 until 30/04/2010

 

Budget page version
1.1

 

Request date

 

Date of latest update
29/11/2009

 

	 	 	 	 	 
	 	 	File number:	 	42073
	 	 	Preparation Date:	 	29/11/2009
	 	 	Company	 	Alcobra
	 	 	Company Number	 	6336

 

	 	 	 
	A. Human Resources	 	 
	Total Human Resources	 	612,000
	 	 
	B. Materials and consumable tools	 	 
	Total Materials	 	120,000
	 	 
	C. Subcontractors	 	 
	Total Subcontractors	 	1,282,300
	 	 
	E. Miscellaneous	 	 
	Total	 	80,000
	
         

         
	 
	 	 	Total in NIS 2,094,300
	 	 	Grant 30% 628,290

 

Notes:

A. The person
performing the research shall be entitled to payments only with respect to expenses made and registered in a special account (including
registration of work hours of the researchers working in this research), and in accordance with the budget instructions of the
Office of the Chief Scientist at the Ministry of Trade and Employment.

 

B. This budget
page is in effect only after signing the letter of approval

 

Signature:

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
        /s/ 
	 	 	 	
        /s/
Alcobra Ltd. 
	 	 	 	
	 	 
	 	 	Office	 	 	 	Company	 	 	 	Date	 	 

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    

 

[Free Translation
from Hebrew]

 

Alcobra Ltd.

number at the registrar
of companies: 514098995

 

	 	 	 
	To	 	 
	Industrial Research and Development Administration, Office of Chief Scientist	 	Date: 3.12.09
	Ministry of Industry, Trade and Employment	 	Company: 6336
	5 Bank Israel, PO Box 3166	 	 
	Jerusalem	 	 

 

Dear Sir,

 

Re: Undertaking
Letter and Notice re Commencement of Performance of Approved R&D Plan

Subject: Development
of Treatment for Attention Deficit Disorder and Memory Impairment 

 

File Number: 42073

 

We hereby inform
you that we commenced performing the approved plan, according to the referenced approval letter on 01.05.09.

 

	 	1.	We declare and undertake to comply with all the provisions of the Law for the Encouragement of Research and Development in Industry 5744-1984 (hereinafter the “Law”), and including:

 

	 	a.	the obligation not to transfer to another the knowledge, the rights on the knowledge and the manufacturing rights deriving from the research and development without the approval of the research committee.

 

	 	b.	to pay royalties and file all reports according to the Law and the Regulations for the Encouragement of Research and Development in Industry (Rate of Royalties and Rules for their Application), 5756-1996 (hereinafter the “Royalties Regulations”) and the procedures of the Industrial Research and Development Administration (hereinafter the “Administration”).

 

	 	2.	We declare that we have read all instructions and procedures for financial reporting for R&D purposes and we will comply with them, including in connection with the computerized system for the reporting on hours in assignment to tasks.

 

	 	3.	
        We consent to the attribution of this file
        numbered: 42073 to plan 42073

        subject: Development
        of Treatment for Attention Deficit Disorder and Memory Impairment.

 

	 	4.	Additional undertakings:

 

	 	Royalties shall be paid on income from Metadoxin Extended (Controlled) Release Tablets.

 

 

	 	5.	We hereby declare that we have separated and distinguished account/s in the framework of our financial bookkeeping for the purpose of performing this plan. The recordings made in the account/s are direct, chronological, primary, systematic and only according to documentation.

 

	 	6.	We hereby declare that we are aware that the referenced grant shall be paid subject to the terms of the approval and according to the Administration’s procedures.

 

	 	7.	The attached budget, including its details, terms and appendices constitutes a binding framework. Expenses deviating from this detailed framework will not be recognized, unless under the approval of the Administration.

 

	 	8.	Procedures:

 

	 	a.	The company shall not be entitled to advancement, and all payments shall be in accordance with the financial report.

 

	 	b.	Any additional payment shall be executed according to a detailed financial report which corresponds to the Administration’s procedures. Payment shall be made after review of the aforesaid report. The grant’s recipient is obliged to file a financial report once every three months and a technical report at least once every half a year, and this on the Administration’s forms or in the same format.

 

	 	c.	The truthfulness of the financial report shall be confirmed by an authorized representative of the company, and documents witnessing actual payments to subcontractors shall be attached, if such expense is reported.

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    
 

	 	d.	Any payment with respect to the approved grant shall be considered as advanced payment only until the approval of the final report. Until the final report, no more than 90% (including ongoing advancements) shall be paid from the lower of the budgeted grant or the expense in the financial report. The remaining balance shall be paid only following receipt of a final financial report and a final technical report together with confirmation from an accountant on behalf of the company. The payment shall be made following examination of the reports by representatives of the Administration.

 

	 	e.	The company’s books of accounts, including the company’s balance sheets, shall be open for review of the Administration during a period of 7 years from the commencement of performance of the approved plan, or 6 years from filing the final financial report, the later of the two.

 

	 	f.	The Administration will have the right to setoff any sum due from the recipient of the support out of grant approved hereby.

 

	 	g.	The grant’s recipient is not entitled to stop performing the plan without the prior written approval from the head of the Administration. If the plan is ceased without such approval, the Administration may and shall be entitled to demand the return of the grant plus interest and linkage differentials in accordance with the law.

 

	 	h.	The grant’s recipient is obligated to file a final financial report approved by an accountant on its behalf in a format acceptable to the Office of the Chief Scientist and a final technical report to the approved plan, no later than 3 months from the date of completion of the approved plan.

 

	 	i.	The Administration is entitled to demand additional technical reports at any time.

 

	 	j.	An expense shall not be recognized unless the consideration therefor is paid, except overhead in salaries item.

 

	 	k.	In the final financial report only expenses accumulated during the approved research period and paid no later than 60 days from its termination shall be recognized.

 

	 	l.	The Administration may demand interest and linkage differentials as provided by law on any sum due to it from the recipient of the grant.

 

	 	9.	The abovementioned terms do not derogate from any statute and law applicable to the grant for this file.

 

	 	10.	We hereby
undertake to comply with intellectual property laws as shall be practiced in Israel from time to time, and we consent that if
we are convicted for violation of any of the intellectual property laws the Administration shall be entitled to retrospectively
terminate any benefit granted by you, including grant, loan, benefit or any other financial advantage, or any part of such benefit,
and demand their repayment including interest and linkage differentials, according to the law.

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    
 

Signature
confirmation for the company

 

The undersigned accountant
Shai Einstein hereby confirms that ____________ is lawfully registered in Israel; that Messrs. Rina Yamin who have signed this
agreement on its behalf, have signed it before me and are authorized to do so on its behalf; that their signature on this agreement
binds the company.

 

	3.12.09	 	/s/
	Date	 	Signature and stamp 
	 	 	 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	/s/	 	 	 	Rina Yamin	 	 	 	CEO	 	 	 	Alcobra Ltd.
	 	 	 	 	 	 	 
	
 

	 	 	 	
 

	 	 	 	
 

	 	 	 	
 

	Signature	 	 	 	Name	 	 	 	Position	 	 	 	Company’s stamp

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

    	 

    

 

[Free Translation
from Hebrew]

 

State of Israel

Ministry of
Trade and Industry

Industrial Research
and Development Administration

Office of Chief
Scientist

 

Jerusalem, ______________

Letter of Approval
Number: 42073

(Fiscal regulation:
38020101)

Group: 13

 

To:

Alcobra Ltd. 

POB – 

Givatayim 53454

Appendix
to Letter of Approval

 

Compliance with
Intellectual Property Laws

 

We have acknowledged
your undertaking from 03.12.09 to comply with intellectual property laws as shall be practiced in Israel from time to time, that
if you are convicted for violation of the intellectual property laws of Israel, by a final and un-appealable judgment in an Israeli
court, we shall be entitled to terminate any benefit granted to you by the Industrial Research and Development Administration,
including grant, loan, tax benefit or any other financial advantage, or any part of such benefit, and demand their return including
interest and linkage differentials according to the law.

 

	 
	Sincerely,
	 
	/s/
	Dr. Eli Ofer
	The Chief Scientist

 

    	{Exhibit 10.8 -- Letter of Approval from the Office of Chief Scientist; 1}

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]